Filing Flows › Opus Genetics (IRD) › Q4 2025
Opus Genetics (IRD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Opus Genetics (IRD) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), -10% from a year earlier and +26% from the quarter before. Operating margin was -296.3%, net loss $16.5M (427.5% of revenue).
Opus Genetics, Q4 2025: revenue $3.9M (-10% year over year), operating margin -296.3%, net loss $16.5M, operating cash flow −$9.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9M | +26% | -10% |
| Operating profit | −$11.5M | — | — |
| Net earnings | −$16.5M | — | — |
| Operating cash flow | −$9.8M | — | — |
What changed
Revenue was $3.9M in Q4 2025, down 10% year over year and up 26% from the previous quarter.
Operating costs exceeded revenue by $11.5M, an operating margin of -296.3%. Total costs fell 64% while revenue fell 10%. The fastest-growing cost line was Research & development (+48%). The quarter ended with a net loss of $16.5M, narrower than the previous quarter's $17.5M loss.
Operating cash flow was −$9.8M. Non-cash charges added back $13K of depreciation and $774K of share-based compensation. Working capital and other items added $5.9M.
Questions
What was Opus Genetics' revenue in the fourth quarter 2025?
Opus Genetics (IRD) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), -10% from a year earlier and +26% from the quarter before.
Was Opus Genetics profitable in the fourth quarter 2025?
Operating loss was $11.5M (-296.3% of revenue) and net loss $16.5M.
Source: Opus Genetics 10-K on SEC EDGAR.